IP Verse

E. R. Squibb & Sons, L.l.c. opposition analysis

COMPANY ANALYSIS

Latest patents of E. R. Squibb & Sons, L.l.c. opposed by its competitors

Patent:

EP3597216

Grant Date:

Aug 24, 2022

Title:

Human Antibodies That Bind Lymphocyte Activation Gene-3 (Lag-3) And Uses Thereof

Oppositions:

Patent:

EP2905030

Grant Date:

Nov 6, 2019

Title:

Human Antibodies That Bind Lymphocyte Activation Gene-3 (Lag-3) And Uses Thereof

Oppositions:

Patent:

EP2439273

Grant Date:

Feb 27, 2019

Title:

Human Monoclonal Antibodies To Programmed Death 1(Pd-1) And Methods For Treating Cancer Using Anti-Pd-1 Antibodies Alone Or In Combination With Other Immunotherapeutics

Oppositions:

Patent:

EP2501822

Grant Date:

Aug 16, 2017

Title:

Methods For Enhanced Protein Production

Oppositions:

Latest patents of E. R. Squibb & Sons, L.l.c. opposed by its competitors

Patent Number	Grant Date	Title	Total Oppositions
EP3597216	Aug 24, 2022	Human Antibodies That Bind Lymphocyte Activation Gene-3 (Lag-3) And Uses Thereof	5
EP2905030	Nov 6, 2019	Human Antibodies That Bind Lymphocyte Activation Gene-3 (Lag-3) And Uses Thereof	1
EP2439273	Feb 27, 2019	Human Monoclonal Antibodies To Programmed Death 1(Pd-1) And Methods For Treating Cancer Using Anti-Pd-1 Antibodies Alone Or In Combination With Other Immunotherapeutics	1
EP2501822	Aug 16, 2017	Methods For Enhanced Protein Production	2

Competitors of E. R. Squibb & Sons, L.l.c.

REGENERON PHARMACEUTICALS, INC.

APPLEYARD LEES IP LLP

DF-MP DORRIES FRANK-MOLNIA & POHLMAN PATENTANWALTE RECHTSANWALTE PARG MBB

Want to track E. R. Squibb & Sons, L.l.c.?

Feel free to send us a message here and we will get back to you